Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody.